| |
| |
|
| Insider
Information: |
Deschatelets Pascal |
| Relationship: |
Chief Scientific Officer |
| City: |
Crestwood |
| State: |
KY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
1,140,483 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$48,755,648 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,140,483 |
|
|
| Total
Value |
$48,755,648 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
5
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -164.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Apellis Pharmaceuticals Inc |
APLS |
Chief Scientific Officer |
2024-05-20 |
1,140,483 |
2018-05-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
80 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-06-17 |
4 |
OE |
$2.67 |
$88,123 |
D/D |
33,005 |
931,280 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-07-08 |
4 |
AS |
$47.95 |
$575,400 |
D/D |
(12,000) |
937,780 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-07-08 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
949,780 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-08-08 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
956,280 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-08-08 |
4 |
AS |
$62.50 |
$750,000 |
D/D |
(12,000) |
944,280 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-09-08 |
4 |
AS |
$63.98 |
$767,760 |
D/D |
(12,000) |
950,780 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-09-08 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
962,780 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-10-10 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
969,280 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-10-10 |
4 |
AS |
$57.50 |
$690,000 |
D/D |
(12,000) |
957,280 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• – – |
2022-11-08 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
975,780 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• – – |
2022-11-08 |
4 |
AS |
$46.47 |
$557,640 |
D/D |
(12,000) |
963,780 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-12-08 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
982,280 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-12-08 |
4 |
AS |
$47.50 |
$570,000 |
D/D |
(12,000) |
970,280 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-12-29 |
4 |
OE |
$3.67 |
$25,690 |
D/D |
7,000 |
977,280 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-01-09 |
4 |
AS |
$46.08 |
$552,960 |
D/D |
(12,000) |
983,780 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-01-09 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
995,780 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
19,634 |
1,003,414 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-01-20 |
4 |
D |
$52.05 |
$121,068 |
D/D |
(2,326) |
1,001,088 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-01-27 |
4 |
D |
$52.77 |
$43,905 |
D/D |
(832) |
1,000,256 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-02-08 |
4 |
AS |
$54.45 |
$653,400 |
D/D |
(12,000) |
1,006,756 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-02-08 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
1,018,756 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-02-10 |
4 |
D |
$51.21 |
$58,072 |
D/D |
(1,134) |
1,005,622 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• – – |
2023-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,886 |
1,015,508 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• – – |
2023-02-21 |
4 |
D |
$58.50 |
$69,908 |
D/D |
(1,195) |
1,014,313 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-03-08 |
4 |
AS |
$63.79 |
$765,480 |
D/D |
(12,000) |
1,020,813 |
0 |
% |
|
80 Records found
|
|
Page 2 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
